Apixaban
- Generic Name
- Apixaban
- Brand Names
- Eliquis, Apixaban Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C25H25N5O4
- CAS Number
- 503612-47-3
- Unique Ingredient Identifier
- 3Z9Y7UWC1J
- Background
Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases. It is marketed under the name Eliquis. Apixaban was approved by the FDA on December 28, 2012.
- Indication
Apixaban is indicated for reducing the risk of stroke and systemic embolism in patients who have nonvalvular atrial fibrillation, prophylaxis of deep vein thrombosis(DVT) leading to pulmonary embolism(PE) in patients after a hip or knee replacement surgery, and treatment of DVT and PE to reduce the risk of recurrence.
- Associated Conditions
- Deep Vein Thrombosis, Deep vein thrombosis recurrent, Pulmonary Embolism, Recurrent Pulmonary Embolism (Disorder), Stroke, Systemic Embolism
- Associated Therapies
- -
Real-world Comparative Effectiveness of Apixaban Versus Vitamin K Antagonist
- First Posted Date
- 2016-02-22
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 18591
- Registration Number
- NCT02687854
Apixaban in Hemodialysis
- First Posted Date
- 2016-02-03
- Last Posted Date
- 2016-08-30
- Lead Sponsor
- Jewish General Hospital
- Target Recruit Count
- 7
- Registration Number
- NCT02672709
- Locations
- 🇨🇦
Jewish General Hospital, Montreal, Canada
Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, and Apixaban in Non-Valvular Atrial Fibrillation
- Conditions
- Interventions
- First Posted Date
- 2016-01-28
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- National Cheng-Kung University Hospital
- Target Recruit Count
- 3672
- Registration Number
- NCT02666157
- Locations
- 🇨🇳
E-DA Hospital, Kaohsiung, Taiwan
🇨🇳National Cheng Kung University Hospital, Tainan, Tainan City, Taiwan
🇨🇳Tainan Hospital Ministry of Health and Welfare, Tainan, Tainan City, Taiwan
Anti-Thrombotic Strategy After Trans-Aortic Valve Implantation for Aortic Stenosis
- Conditions
- Interventions
- First Posted Date
- 2016-01-27
- Last Posted Date
- 2021-02-25
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 1510
- Registration Number
- NCT02664649
- Locations
- 🇫🇷
ACTION Study Group, Institut de Cardiologie, Centre Hospitalier Universitaire Pitié Salpêtrière (APHP), UPMC, Paris, France
🇮🇹Unità Operativa di Cardiologia Fondazione Gabriele Monasterio C.N.R., Massa, Via Aurelia Sud, Italy
🇩🇪Division of Cardiology and Angiology II, University Heart Center Freiburg, Bad Krozingen, Südring 15, Germany
Venous Thromboembolism in Renally Impaired Patients and Direct Oral Anticoagulants
- Conditions
- Interventions
- First Posted Date
- 2016-01-26
- Last Posted Date
- 2022-10-19
- Target Recruit Count
- 203
- Registration Number
- NCT02664155
- Locations
- 🇫🇷
CHU Toulouse, Toulouse 9, France
🇫🇷CH de Valenciennes, Valenciennes, France
🇫🇷CH ARRAS, Arras, Boulevard Georges Besnier, France
APIXABAN in the Prevention of Stroke and Systemic Embolism in Patients With Atrial Fibrillation in Real-Life Setting in France SNIIRAM Study
- Conditions
- Interventions
- First Posted Date
- 2015-12-28
- Last Posted Date
- 2022-05-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 321501
- Registration Number
- NCT02640222
Comparison of Brain Perfusion in Rhythm Control and Rate Control of Persistent Atrial Fibrillation
- First Posted Date
- 2015-12-17
- Last Posted Date
- 2019-01-28
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 200
- Registration Number
- NCT02633774
- Locations
- 🇰🇷
Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea, Republic of
Pharmacokinetics of Apixaban in Nephrotic Syndrome
- First Posted Date
- 2015-11-06
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 21
- Registration Number
- NCT02599532
- Locations
- 🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Apixaban or Dalteparin in Reducing Blood Clots in Patients With Cancer Related Venous Thromboembolism
- Conditions
- Interventions
- First Posted Date
- 2015-10-23
- Last Posted Date
- 2020-08-04
- Lead Sponsor
- Academic and Community Cancer Research United
- Target Recruit Count
- 300
- Registration Number
- NCT02585713
- Locations
- 🇺🇸
Mayo Clinic in Arizona, Scottsdale, Arizona, United States
🇺🇸Cancer Research Consortium of West Michigan NCORP, Grand Rapids, Michigan, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
Apixaban as Treatment of Venous Thrombosis in Patients With Cancer: The CAP Study
- First Posted Date
- 2015-10-20
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- University Hospital, Akershus
- Target Recruit Count
- 300
- Registration Number
- NCT02581176
- Locations
- 🇳🇴
Oslo University Hospital, Oslo, Norway
🇳🇴Stavanger University Hospital, Stavanger, Norway
🇳🇴Volda Hospital, Volda, Norway
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.